Synthesis and antimicrobial activities of novel 1H-dibenzo[a,c]carbazoles from dehydroabietic acid

Facile Synthesis of Substituted Furo- and Pyrano-Carbazoles

“…for C 14 H 7 NO 3 : C,70.88;H,2.95;N,5.90%. Found: C,70.94;H,2.98;N,5,6,2,phenanthridin-8-ones (6) and 3,4,5,carbazol-2(13H)-ones (7) General procedure. An appropriate mixture of the respective 1-hydroxycarbazoles (1, 1 mmol) and ethyl 2-oxocyclohexan-2-carboxylate (1 mmol) is treated 2974 K. PRABAKARAN AND K. J. R. PRASAD with fused ZnCl 2 =POCl 3 (1.5 g=6 mL) at 80 C for 6 h. The reaction was monitored by TLC.…”

“…[1][2][3][4][5] Naturally occurring 1-oxygenated carbazoles have attracted great interest because of their diverse and significant biological activity. [6] These alkaloids are mainly extracted from species of the genera Murraya and Clausena, and in the case of 2-and 3-substituted families, their biogenesis has been established.…”

Cytotoxic Activities of Amino Acid‐Conjugate Derivatives of Abietane‐Type Diterpenoids against Human Cancer Cell Lines

“…Compound 1 is converted to dehydroabietic acid ( ¼ abieta-8(14), 9(11),12-trien-18-oic acid; 11) by disproportionation with heat and catalysis. Because of their potential bioactivities, various derivatives of 1 and 11 have been prepared and evaluated for their antimicrobial activities [6], maxi-K (BK) channel-opening activity [7], and cytotoxicities against several cancer cell lines [8 -12]. Recently, compound 11 has been reported to have peroxisome proliferatoractivated receptor (PPAR)a/g dual activator property [1], inhibitory effect on EpsteinÀBarr virus early antigen (EBV-EA) activation [2] [3], and gastroprotective effect [4].…”

The Synthesis and Antimicrobial Activity of Heterocyclic Derivatives of Totarol

“…Standard protic and Lewis acidic conditions did not offer a general solution. 27–28 The Fischer indole synthesis on our hindered ketone required us to investigate conditions on a model system. A model system of dimethyl-β-tetralone 18 was employed to find optimal reaction conditions (Table 2).…”